Syndax Pharmaceuticals
Markets targeted therapies for acute leukemias and chronic graft-versus-host disease.
$19.39
After-hours close−0.15 (−0.77%)
At close$19.54(−3.08%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 125.11%Insiders 1.61%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 88.61M · Float 80.23M · 90.5% free float
Institutions13F, as of Jun 30, 2026
253 holders · 110.86M shares · 39 new positions · 134 increased · 77 reduced · 42 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.02M | 10.18% | +765.6K | Aug 7, 2026 |
| Kynam Capital Management, LP | 8.05M | 9.09% | 0 | Aug 14, 2026 |
| Goldman Sachs Group Inc | 5.86M | 6.61% | +864.5K | Aug 14, 2026 |
| State Street Corp | 5.66M | 6.39% | +1.23M | Aug 7, 2026 |
| Bank of America Corp /DE/ | 4.05M | 4.57% | −204.7K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.93M | 4.43% | +105.3K | Aug 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 3.78M | 4.27% | 0 | Aug 14, 2026 |
| Eversept Partners, LP | 2.80M | 3.16% | −87.4K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Kynam Capital Management, LP | 9.98% | 8.52M | 13G | Feb 14, 2025 ↗ |
| BlackRock, Inc. | 7.80% | 6.74M | 13G | Apr 17, 2025 ↗ |
| The Goldman Sachs Group, Inc. | 6.50% | 5.58M | 13G | Aug 13, 2025 ↗ |
| State Street Corporation | 6.40% | 5.66M | 13G | Aug 7, 2026 ↗ |
| Vanguard Capital Management | 5.05% | 4.46M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Michael A. Metzger | director, officer: Chief Executive Officer | 484.8K | 0.55% | Jul 9, 2026 |
| Dennis Podlesak | director | 239.8K | 0.27% | Feb 6, 2026 |
| Keith A. Goldan | officer: Chief Financial Officer | 139.3K | 0.16% | Jun 2, 2026 |
| Keith Katkin | director | 124.0K | 0.14% | Feb 6, 2026 |
| Jennifer Jarrett | director | 114.0K | 0.13% | Feb 6, 2026 |
| Pierre Legault | director | 114.0K | 0.13% | Feb 6, 2026 |
| Martin H. Jr. Huber | director | 103.0K | 0.12% | Feb 6, 2026 |
| Nicholas A.J. Botwood | officer: Head of R&D, CMO | 60.9K | 0.07% | Jun 12, 2026 |
| Aleksandra Rizo | director | 49.0K | 0.06% | Feb 6, 2026 |
10 ten-percent owners hold 4.44M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (1.36M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 8, 2026 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 32,375 | $24.24 | 484,843 |
| Jun 12, 2026 | Nicholas A.J. Botwoodofficer: Head of R&D, CMO | Sale | 31,235 | $18.14 | 60,885 |
| Jun 11, 2026 | Nicholas A.J. Botwoodofficer: Head of R&D, CMO | Sale | 34,280 | $18.00 | 60,885 |
| Jun 1, 2026 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 6,847 | $18.99 | 484,843 |
| Jun 1, 2026 | Keith A. Goldanofficer: Chief Financial Officer | Sale | 1,177 | $18.99 | 139,252 |
| Feb 9, 2026 | Keith A. Goldanofficer: Chief Financial Officer | Sale | 3,410 | $21.03 | 140,429 |
| Feb 9, 2026 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 17,159 | $21.03 | 491,690 |
| Feb 6, 2026 | Keith A. Goldanofficer: Chief Financial Officer | Sale | 2,082 | $20.62 | 143,839 |
| Feb 6, 2026 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 7,412 | $20.62 | 508,849 |
| Sep 8, 2025 | Michael A. Metzgerdirector, officer: Chief Executive Officer | Sale | 157,307 | $16.41 | 298,661 |
CongressHouse and Senate disclosures
Not reported.